Category: Latest News

Control of catheter associated biofilms through efflux inhibition

Control of catheter associated biofilms through efflux inhibition

Posted on by Targeting Phage Therapy
Pr Brian Jones, from school of Pharmacy and Biomolecular Sciences, University of Brighton, United Kingdom will present his study on “Control of catheter associated biofilms through efflux inhibition“. According to him: “Proteus mirabilis poses particular problems in the care of individuals undergoing long-term urethral catheterization. This organism forms extensive crystalline biofilm structures on catheter surfaces…
Posted on May 12, 2017
Read More
Development of Infection-responsive surface coatings for bacteriophage delivery in the catheterised urinary tract

Development of Infection-responsive surface coatings for bacteriophage delivery in the catheterised urinary tract

Posted on by Targeting Phage Therapy
Pr Jones from School of Pharmacy and Biomolecular Sciences, University of Brighton, United Kingdom will talk about will talk about his study on “Development of Infection-responsive surface coatings for bacteriophage delivery in the catheterised urinary tract“. He summarizes his talk in following: “Indwelling urethral catheters (IUC) are widely used for long-term bladder management but are…
Posted on May 12, 2017
Read More
Do phages or phage-based products select for less virulent bacterial population? University of Wroclaw, Poland

Do phages or phage-based products select for less virulent bacterial population? University of Wroclaw, Poland

Posted on by Targeting Phage Therapy
Prof. dr hab. Zuzanna Drulis-Kawa from the Department of Pathogen Biology and Immunology Institute of Genetics and Microbiology at University of Wroclaw, Poland, summarizes her talk in following :  “Most phages target bacterial surface molecules, especially those of carbohydrate nature, which are the dominant phage receptors. Surface glycans and glycoconjugates (polysaccharides PS) such as capsules and lipopolysaccharides…
Posted on May 9, 2017
Read More
Lytic bacteriophages in the treatment of biofilm-forming bacteria involved in prosthetic joint infections

Lytic bacteriophages in the treatment of biofilm-forming bacteria involved in prosthetic joint infections

Posted on by Targeting Phage Therapy
Dr. Mariagrazia Di Luca is a Medical Microbiologist. She received her PhD in Microbiology and Genetics from the University of Pisa in 2010, studying the role of a type VII secretion system (ESX-5) in Mycobacterium tuberculosis and its involvement in the virulence of the microorganism. After the PhD, she attended a five year Specialization School in Microbiology…
Posted on May 9, 2017
Read More
Bacteriophage therapy for lung infections: Presentation of the recent scientific advances by Martin Witzenrath

Bacteriophage therapy for lung infections: Presentation of the recent scientific advances by Martin Witzenrath

Posted on by Targeting Phage Therapy
In 2016, during the previous congress on Phage Therapy, Prof. Martin Witzenrath, from Charité – Universitätsmedizin Berlin, Germany, was awarded for his scientific contribution regarding the phage therapy and especially about Bacteriophage therapy for lung infections. This year during Florence Congress, Prof. Witzenrath will update the scientific advances on this strategic topic. Prof. Martin Witzenrath, physician and…
Posted on April 27, 2017
Read More

Do phages or phage-based products select for less virulent bacterial population?

Posted on by Targeting Phage Therapy
According to Prof. dr hab. Zuzanna Drulis-Kawa from the Department of Pathogen Biology and Immunology Institute of Genetics and Microbiology at University of Wroclaw, Poland: “Most phages target bacterial surface molecules, especially those of carbohydrate nature, which are the dominant phage receptors. Surface glycans and glycoconjugates (polysaccharides PS) such as capsules and lipopolysaccharides (LPS) serve as molecular…
Posted on April 27, 2017
Read More

What is the impact of virulent bacteriophages on vibrio cholerae infection and their use in preventing cholera?

Posted on by Targeting Phage Therapy
During Florence Targeting Antibiotic Resistance congress, Dr Minmin Yen will give a presentation about the impact of virulent bacteriophages on vibrio cholerae infection and their use in preventing cholera. Minmin Yen is working in microbiology at Tufts University, Sackler School of Graduate Biomedical Sciences. In 2016, she was awarded for her short oral presentation during Paris…
Posted on April 27, 2017
Read More

Tuberculosis and antibiotic resistance: researchers in Lille invent a new prototype drug

Posted on by Targeting Phage Therapy
Lille researchers (Inserm, University of Lille, Pasteur Institute of Lille, CNRS) * invented a prototype drug (SMARt-420 **) capable of suppressing resistance to ethionamide, an antibiotic used to treat tuberculosis. This work is published in the journal Science *** dated March 17, 2017 and opens a new way in the fight against resistance to antibiotics.…
Posted on March 30, 2017
Read More

Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance

Posted on by Targeting Phage Therapy
More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on governments and industry to work in parallel in taking comprehensive action against drug-resistant infections – socalled ‘superbugs’ – with a joint declaration launched today at the World Economic Forum in Davos, Switzerland. The statement sets out…
Posted on March 30, 2017
Read More